NO319571B1 - Anvendelse av et defektivt, rekombinant adenovirus. - Google Patents

Anvendelse av et defektivt, rekombinant adenovirus. Download PDF

Info

Publication number: NO319571B1
Authority: NO; Norway
Prior art keywords: defective; adenovirus; gene; cells; recombinant
Prior art date: 1993-03-03

Application number

NO19953329A

Other languages

English (en)

Norwegian (no)

Other versions

NO953329L (no

NO953329D0 (no

Inventor

Michel Perricaudet

Pascale Briand

Original Assignee

Agronomique Inst Nat Rech

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-03

Filing date

1995-08-24

Publication date

2005-08-29

1995-08-24 Application filed by Agronomique Inst Nat Rech, Aventis Pharma Sa filed Critical Agronomique Inst Nat Rech

1995-08-24 Publication of NO953329L publication Critical patent/NO953329L/no

1995-08-24 Publication of NO953329D0 publication Critical patent/NO953329D0/no

2005-08-29 Publication of NO319571B1 publication Critical patent/NO319571B1/no

Links

241000701161 unidentified adenovirus Species 0.000 title claims abstract description 35
230000002950 deficient Effects 0.000 title claims abstract description 28
108090000623 proteins and genes Proteins 0.000 claims abstract description 64
102000004169 proteins and genes Human genes 0.000 claims description 19
230000014509 gene expression Effects 0.000 claims description 17
230000008397 ocular pathology Effects 0.000 claims description 13
230000007170 pathology Effects 0.000 claims description 8
230000010076 replication Effects 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
239000000825 pharmaceutical preparation Substances 0.000 claims description 6
206010038910 Retinitis Diseases 0.000 claims description 3
239000012634 fragment Substances 0.000 claims description 3
208000030533 eye disease Diseases 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 43
238000002347 injection Methods 0.000 description 19
239000007924 injection Substances 0.000 description 19
241000700605 Viruses Species 0.000 description 13
238000000034 method Methods 0.000 description 9
238000012546 transfer Methods 0.000 description 7
210000000608 photoreceptor cell Anatomy 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
230000000694 effects Effects 0.000 description 5
230000006801 homologous recombination Effects 0.000 description 5
238000002744 homologous recombination Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
239000013598 vector Substances 0.000 description 5
108020004414 DNA Proteins 0.000 description 4
201000007737 Retinal degeneration Diseases 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
210000001328 optic nerve Anatomy 0.000 description 4
230000004258 retinal degeneration Effects 0.000 description 4
238000010186 staining Methods 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241001135569 Human adenovirus 5 Species 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
208000007014 Retinitis pigmentosa Diseases 0.000 description 3
241000714474 Rous sarcoma virus Species 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
210000001525 retina Anatomy 0.000 description 3
230000002207 retinal effect Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010003694 Atrophy Diseases 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
208000003098 Ganglion Cysts Diseases 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
208000005400 Synovial Cyst Diseases 0.000 description 2
230000037444 atrophy Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
230000006866 deterioration Effects 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000009826 distribution Methods 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
239000000203 mixture Substances 0.000 description 2
210000004398 oculomotor muscle Anatomy 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
230000010473 stable expression Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000013519 translation Methods 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
229940099259 vaseline Drugs 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
206010001557 Albinism Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
206010019899 Hereditary retinal dystrophy Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
201000003533 Leber congenital amaurosis Diseases 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
108020005196 Mitochondrial DNA Proteins 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010055078 Rab geranylgeranyltransferase Proteins 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010057430 Retinal injury Diseases 0.000 description 1
108090000820 Rhodopsin Proteins 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
108060008724 Tyrosinase Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000001775 bruch membrane Anatomy 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
210000002555 descemet membrane Anatomy 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
210000000871 endothelium corneal Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000003128 head Anatomy 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000002406 microsurgery Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
201000007909 oculocutaneous albinism Diseases 0.000 description 1
229940069265 ophthalmic ointment Drugs 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
231100000255 pathogenic effect Toxicity 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004491 retinal development Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000003786 sclera Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
229950004616 tribromoethanol Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Virology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Ophthalmology & Optometry (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

NO19953329A 1993-03-03 1995-08-24 Anvendelse av et defektivt, rekombinant adenovirus. NO319571B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9302438A FR2702152B1 (fr)	1993-03-03	1993-03-03	Virus recombinants et leur utilisation en thérapie génique.
PCT/FR1994/000220 WO1994020146A1 (fr)	1993-03-03	1994-02-28	Adenovirus recombinants et leur utilisation en therapie genique pour le traitement des pathologies oculaires

Publications (3)

Publication Number	Publication Date
NO953329L NO953329L (no)	1995-08-24
NO953329D0 NO953329D0 (no)	1995-08-24
NO319571B1 true NO319571B1 (no)	2005-08-29

Family

ID=9444602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19953329A NO319571B1 (no)	1993-03-03	1995-08-24	Anvendelse av et defektivt, rekombinant adenovirus.

Country Status (15)

Country	Link
EP (1)	EP0687184B1 (de)
JP (1)	JP3835809B2 (de)
AT (1)	ATE220923T1 (de)
AU (1)	AU693782B2 (de)
CA (1)	CA2154355A1 (de)
DE (1)	DE69431046T2 (de)
DK (1)	DK0687184T3 (de)
ES (1)	ES2181710T3 (de)
FR (1)	FR2702152B1 (de)
HU (1)	HU218900B (de)
NO (1)	NO319571B1 (de)
NZ (1)	NZ262135A (de)
PT (1)	PT687184E (de)
WO (1)	WO1994020146A1 (de)
ZA (1)	ZA941426B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5792751A (en) *	1992-04-13	1998-08-11	Baylor College Of Medicine	Tranformation of cells associated with fluid spaces
FR2726575B1 (fr) *	1994-11-09	1996-12-20	Rhone Poulenc Rorer Sa	Virus recombinants, preparation et utilisation en therapie genique
IL113052A0 (en) *	1994-03-23	1995-06-29	Rhone Poulenc Rorer Sa	Recombinant viruses, their preparation and their use in gene therapy
FR2717823B1 (fr) *	1994-03-23	1996-04-26	Rhone Poulenc Rorer Sa	Virus recombinants, préparation et utilisation en thérapie génique.
FR2717824B1 (fr) *	1994-03-25	1996-04-26	Rhone Poulenc Rorer Sa	Virus recombinants, préparation et utilisation en thérapie génique.
FR2718150B1 (fr)	1994-03-29	1996-04-26	Rhone Poulenc Rorer Sa	Virus recombinants, préparation et utilisation en thérapie génique.
US5827702A (en) *	1994-10-31	1998-10-27	Genentech, Inc.	Ocular gene therapy
US6107027A (en) *	1994-12-14	2000-08-22	University Of Washington	Ribozymes for treating hepatitis C
US6696423B1 (en)	1997-08-29	2004-02-24	Biogen, Inc.	Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6489305B1 (en)	1998-05-08	2002-12-03	Canji, Inc.	Methods and compositions for the treatment of ocular diseases
DE60022549T2 (de) *	1999-12-30	2006-05-18	Aventis Pharma S.A.	Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut
FR2803207B1 (fr) *	1999-12-30	2004-04-30	Aventis Pharma Sa	Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
US6821775B1 (en)	2000-02-11	2004-11-23	Genvec, Inc.	Viral vector encoding pigment epithelium-derived factor
US20030158112A1 (en)	2002-02-15	2003-08-21	Johns Hopkins University School Of Medicine	Selective induction of apoptosis to treat ocular disease
NZ546983A (en)	2003-11-24	2009-05-31	Canji Inc	Reduction of dermal scarring
CN101094688B (zh)	2004-09-13	2013-05-01	建新公司	多聚构建体
HRP20180154T1 (hr)	2010-08-06	2018-03-09	Genzyme Corporation	Pripravci vegf antagonista i njihova uporaba

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0434750B1 (de) *	1988-09-13	1997-07-09	Biosource Technologies, Inc.	Zusammensetzung zur Behandlung von degenerativen Krankheiten des Nervensystems
JPH06506599A (ja) *	1991-04-05	1994-07-28	エディソン　アニマル　バイオテクノロジー　センター，オハイオ　ユニバーシティー	パッケージング配列に相補的なアンチセンス核酸によるレトロウイルスの抑制

1993
- 1993-03-03 FR FR9302438A patent/FR2702152B1/fr not_active Expired - Fee Related
1994
- 1994-02-28 ES ES94908383T patent/ES2181710T3/es not_active Expired - Lifetime
- 1994-02-28 PT PT94908383T patent/PT687184E/pt unknown
- 1994-02-28 JP JP51965094A patent/JP3835809B2/ja not_active Expired - Fee Related
- 1994-02-28 AT AT94908383T patent/ATE220923T1/de not_active IP Right Cessation
- 1994-02-28 CA CA002154355A patent/CA2154355A1/fr not_active Abandoned
- 1994-02-28 AU AU61444/94A patent/AU693782B2/en not_active Ceased
- 1994-02-28 DK DK94908383T patent/DK0687184T3/da active
- 1994-02-28 WO PCT/FR1994/000220 patent/WO1994020146A1/fr not_active Ceased
- 1994-02-28 DE DE69431046T patent/DE69431046T2/de not_active Expired - Fee Related
- 1994-02-28 EP EP94908383A patent/EP0687184B1/de not_active Expired - Lifetime
- 1994-02-28 HU HU9502573A patent/HU218900B/hu unknown
- 1994-02-28 NZ NZ262135A patent/NZ262135A/xx unknown
- 1994-03-01 ZA ZA941426A patent/ZA941426B/xx unknown
1995
- 1995-08-24 NO NO19953329A patent/NO319571B1/no unknown

Also Published As

Publication number	Publication date
WO1994020146A1 (fr)	1994-09-15
ES2181710T3 (es)	2003-03-01
EP0687184A1 (de)	1995-12-20
PT687184E (pt)	2002-12-31
NO953329L (no)	1995-08-24
NO953329D0 (no)	1995-08-24
HU218900B (hu)	2000-12-28
FR2702152A1 (fr)	1994-09-09
ATE220923T1 (de)	2002-08-15
CA2154355A1 (fr)	1994-09-15
DE69431046D1 (de)	2002-08-29
FR2702152B1 (fr)	1995-05-24
AU693782B2 (en)	1998-07-09
AU6144494A (en)	1994-09-26
ZA941426B (en)	1994-10-04
HU9502573D0 (en)	1995-10-30
NZ262135A (en)	2000-12-22
JP3835809B2 (ja)	2006-10-18
DE69431046T2 (de)	2003-02-13
HUT73215A (en)	1996-06-28
JPH08509208A (ja)	1996-10-01
DK0687184T3 (da)	2002-10-28
EP0687184B1 (de)	2002-07-24

Publication	Publication Date	Title
JP7011580B2 (ja)	2022-01-26	網膜色素変性症の治療
US7989426B2 (en)	2011-08-02	Selective induction of apoptosis to treat ocular disease by expression of PEDF
Hauswirth et al.	2000	Ocular gene therapy: quo vadis?
JP3835809B2 (ja)	2006-10-18	組み換えアデノウイルスおよび眼疾患の治療のための遺伝子療法におけるそれらの使用
Spencer et al.	2000	Herpes simplex virus–mediated gene delivery to the rodent visual system
JP2022522996A (ja)	2022-04-21	オトフェリン遺伝子を回復させるａａｖ媒介遺伝子治療
JPH10503361A (ja)	1998-03-31	組換えｐ５３アデノウイルス方法と組成物
US20070264244A1 (en)	2007-11-15	Pigment epithelial cell of the eye, its production and use in therapy of an eye or CNS disease
Fehervari et al.	1997	Gene transfer to ex vivo stored corneas
Mori et al.	2002	Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies
AU780634C (en)	2006-02-23	Gene Therapy for treating ocular-related disorders
JP2004501650A (ja)	2004-01-22	複製欠損アデノウイルスｔｎｆベクター
Ali et al.	1997	Gene therapy for inherited retinal degeneration
Dijkhuizen et al.	1998	Adenoviral vector-mediated gene delivery to injured rat peripheral nerve
JP2006518741A (ja)	2006-08-17	ａｔｏｎａｌ関連因子をコードするベクターを投与することによる耳疾患を治療するための遺伝子治療法
US20030086907A1 (en)	2003-05-08	Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases
Lani-Louzada et al.	2021	Gene therapy strategies for glaucomatous neurodegeneration
CA2595942A1 (en)	2006-08-03	Treatment of degenerative diseases with the x-linked inhibitor of apoptosis
Gupta et al.	2001	Strain‐dependent anterior segment neovascularization following intravitreal gene transfer of basic fibroblast growth factor (bFGF)
Caleo et al.	2002	Expression of BCL‐2 via adeno‐associated virus vectors rescues thalamic neurons after visual cortex lesion in the adult rat
US20020031493A1 (en)	2002-03-14	Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
KR20240000814A (ko)	2024-01-03	망막색소상피에 특이적으로 작동하는 CRISPR/Cas 복합체를 유효성분으로 포함하는 망막질환 치료용 약학조성물
Liu et al.	2007	Glaucoma gene therapy
WO2020258078A1 (zh)	2020-12-30	基于rna定点编辑的抑制脉络膜新生血管形成的方法及试剂
Li et al.	2004	653. Activation of an ATM/chk2-Dependent Pathway Is Required for HSV-1 Protein ICp0 Induced G2/M Cell Cycle Arrest